PMLiVE8h
FDA approves Supernus’ Onapgo to treat advanced Parkinson’s disease
The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection ...
BioSpace7h
Supernus Taps Potential $300M US Opportunity With FDA Win for Parkinson’s Drug-Device Combo
The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...
Healio22h
FDA approves Onapgo for motor fluctuations in adults with Parkinson’s disease
The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...
New Atlas12h
US approves "milestone" Parkinson's treatment for 2025 release
Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.
The American Journal of Managed Care23h
FDA Approves First Subcutaneous Apomorphine Device for Parkinson Disease
The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...
California Healthline5h
California Healthline Daily Edition
The results were presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium held in San Francisco late last month. They were also published in the Journal of ...